A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer

Trial Profile

A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms VITAL
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 02 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 03 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 05 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top